For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Blog
Don’t hinder biosimilar development
In its most recent legislative session, the Florida legislature considered precluding pharmacy benefit managers (PBMs) from holding an investment interest in biosimilar manufacturing. That…
Blog
The unseen costs of banning PBM-owned pharmacies in Tennessee
Tennessee lawmakers recently passed the FAIR Rx Act, which would bar companies from owning pharmacies while also operating a pharmacy benefit manager (PBM) and…
Blog
Trump’s State of the Union: A closer look at the claims
Last night, President Trump delivered a State of the Union address filled with optimism, applause lines, and bold claims about the country’s direction. There…
Search Posts
Study
Rule Forcing Tests for Safer Air Bags Expected Today
Blog
More Confusion on Breast Cancer Screening
When the federal government's Preventive Services Task Force recommended in November 2009 that most women under age 50 should stop having regular…
Blog
The President’s Health Care Fables
The president pushed the health care bill through Congress using a series of fables -- health insurance horror stories…
Op-Eds
The USDA’s Anti-Science Activism
Full Document Available in PDF U.S. Department of Agriculture Secretary Tom Vilsack must…
Blog
Federal Appeals Court Upholds Obamacare’s Individual Mandate in Divided 2-to-1 Vote
The U.S. Sixth Circuit Court of Appeals has upheld the individual mandate contained in the 2010 healthcare law by a 2-to-1 vote, claiming that…
News Release
CEI Slams FDA Vote on Avastin
Washington, D.C., June 29, 2011 — An FDA advisory committee voted today to revoke the approval for breast cancer treatment from the drug Avastin.